Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endoplasmic reticulum-Golgi intermediate compartment 53 kDa protein (LMAN1, also known as ERGIC-53) is a type I integral membrane mannose-specific lectin cycling between the endoplasmic reticulum (ER), the ER-Golgi intermediate compartment (ERGIC), and cis-Golgi. It functions as a cargo receptor for the ER-to-Golgi transport of selected glycoproteins, including blood clotting factors V and VIII, by forming a complex with MCFD2. Loss-of-function mutations result in combined deficiency of coagulation factors V and VIII, an autosomal recessive bleeding disorder. LMAN1 has also been implicated in colorectal tumorigenesis through early mutational inactivation. Its mechanism involves a calcium-dependent, pH-sensitive carbohydrate recognition domain, and it is not a direct target of any approved therapeutic drugs.
Not drug-targeted directly; mutations in LMAN1 disrupt ER-to-Golgi transport of clotting factors V and VIII, leading to combined deficiency (loss of function).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endoplasmic reticulum-Golgi intermediate compartment 53 kDa protein (LMAN1).